Novo Holdings discloses Avalyn Pharma preferred stake
Novo Holdings A/S, a more than ten percent owner of Avalyn Pharma Inc., has filed an initial ownership report showing its preferred stock positions in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Novo Holdings A/S, a more than ten percent owner of Avalyn Pharma Inc., has filed an initial ownership report showing its preferred stock positions in the company. The filing lists holdings of Series A, B, C-1, C-2 and D Preferred Stock, each convertible into voting common stock.
Each preferred share is convertible into voting common stock on a 1-for-19.2417 basis at the holder’s election and will convert automatically upon the closing of Avalyn Pharma’s initial public offering, with no expiration date. These entries disclose existing ownership rather than new purchases or sales.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Novo Holdings A/S
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock | -- | -- | -- |
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Series C-1 Preferred Stock | -- | -- | -- |
| holding | Series C-2 Preferred Stock | -- | -- | -- |
| holding | Series D Preferred Stock | -- | -- | -- |
Holdings After Transaction:
Series A Preferred Stock — 935,466 contracts (Direct);
Series B Preferred Stock — 103,232 contracts (Direct);
Series C-1 Preferred Stock — 1,345,997 contracts (Direct);
Series C-2 Preferred Stock — 290,390 contracts (Direct);
Series D Preferred Stock — 652,649 contracts (Direct)
Footnotes (1)
- F1. The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock is convertible on a 1-for-19.2417 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.
Key Figures
Series D underlying shares: 652,649 shares
Series C-2 underlying shares: 290,390 shares
Series C-1 underlying shares: 1,345,997 shares
+3 more
6 metrics
Series D underlying shares
652,649 shares
Underlying voting common stock for Series D Preferred Stock
Series C-2 underlying shares
290,390 shares
Underlying voting common stock for Series C-2 Preferred Stock
Series C-1 underlying shares
1,345,997 shares
Underlying voting common stock for Series C-1 Preferred Stock
Series B underlying shares
103,232 shares
Underlying voting common stock for Series B Preferred Stock
Series A underlying shares
935,466 shares
Underlying voting common stock for Series A Preferred Stock
Conversion ratio
1-for-19.2417
Preferred stock to voting common stock conversion basis
Key Terms
Series A Preferred Stock, Voting Common Stock, initial public offering, ten percent owner, +1 more
5 terms
Series A Preferred Stock financial
"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock..."
Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.
Voting Common Stock financial
"is convertible on a 1-for-19.2417 basis into voting common stock at any time"
initial public offering financial
"will convert automatically upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
ten percent owner financial
"Novo Holdings A/S is indicated as a ten percent owner of the issuer"
convertible financial
"Preferred Stock is convertible on a 1-for-19.2417 basis into voting common stock"
A convertible is a type of investment that starts as a loan or preferred stake (like a bond or preferred share) but can be exchanged for common shares of the company at a set price or under certain conditions. It matters to investors because it offers a mix of steady income and downside protection like a loan, plus the upside of stock ownership if the company does well—similar to holding a coupon that you can trade for a full ticket if the event becomes valuable.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Novo Holdings A/S report in its Avalyn Pharma (AVLN) Form 3?
Novo Holdings A/S reports its existing holdings of multiple Avalyn Pharma preferred stock series. These include Series A, B, C-1, C-2 and D Preferred Stock, each convertible into voting common stock, establishing Novo Holdings as a significant pre-IPO shareholder.
Which Avalyn Pharma (AVLN) preferred stock series does Novo Holdings A/S hold?
Novo Holdings A/S holds Avalyn Pharma Series A, Series B, Series C-1, Series C-2 and Series D Preferred Stock. Each series is listed separately in the Form 3, with associated underlying voting common stock share amounts for each preferred stock class.
What happens to Novo Holdings A/S’s Avalyn Pharma preferred stock at the IPO?
Novo Holdings A/S’s Avalyn Pharma preferred shares automatically convert to voting common stock upon closing of the company’s initial public offering. This automatic conversion applies to the Series A, B, C-1, C-2 and D Preferred Stock and occurs without an expiration date.
What conversion rate applies to Avalyn Pharma (AVLN) preferred stock held by Novo Holdings A/S?
Avalyn Pharma’s Series A, B, C-1, C-2 and D Preferred Stock held by Novo Holdings A/S convert into voting common stock at a 1-for-19.2417 rate. This uniform conversion ratio applies at the holder’s election and at the company’s initial public offering closing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
